X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4) 4
aged (3) 3
disease-free survival (3) 3
female (3) 3
humans (3) 3
male (3) 3
middle aged (3) 3
oncology (3) 3
1st-line treatment (2) 2
antineoplastic agents - therapeutic use (2) 2
biomarkers (2) 2
colorectal cancer (2) 2
colorectal neoplasms - drug therapy (2) 2
colorectal neoplasms - mortality (2) 2
colorectal neoplasms - pathology (2) 2
fluorouracil (2) 2
leucovorin (2) 2
phenylurea compounds - therapeutic use (2) 2
proteins (2) 2
pyridines - therapeutic use (2) 2
abridged index medicus (1) 1
acquired-resistance (1) 1
adenocarcinoma (1) 1
adenocarcinoma - blood (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - genetics (1) 1
adenocarcinoma - mortality (1) 1
adenocarcinoma - secondary (1) 1
adjuvant chemotherapy (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
biomarkers, tumor - blood (1) 1
biomarkers, tumor - genetics (1) 1
ca-19-9 (1) 1
ca19-9 (1) 1
camptothecin - administration & dosage (1) 1
camptothecin - analogs & derivatives (1) 1
cancer (1) 1
cancer patients (1) 1
cancer therapies (1) 1
carbohydrate antigen 19-9 (1) 1
cediranib (1) 1
chemotherapy (1) 1
class i phosphatidylinositol 3-kinases (1) 1
clinical study (1) 1
clinical trials (1) 1
clinical trials, phase iii as topic (1) 1
colon cancer (1) 1
colonic neoplasms - drug therapy (1) 1
colorectal neoplasms - blood (1) 1
colorectal neoplasms - genetics (1) 1
deoxyribonucleic acid--dna (1) 1
disease progression (1) 1
dna (1) 1
dna mutational analysis (1) 1
dna, neoplasm - blood (1) 1
dna, neoplasm - genetics (1) 1
double-blind (1) 1
double-blind method (1) 1
drug resistance (1) 1
drug therapy (1) 1
fluorouracil - administration & dosage (1) 1
folfirinox (1) 1
genetic predisposition to disease (1) 1
genetic research (1) 1
genetic testing (1) 1
genotype & phenotype (1) 1
hematology, oncology and palliative medicine (1) 1
inhibits growth (1) 1
internal medicine (1) 1
irinotecan (1) 1
kaplan-meier estimate (1) 1
kras mutations (1) 1
leucovorin - administration & dosage (1) 1
liver (1) 1
medical colleges (1) 1
medical prognosis (1) 1
medical research (1) 1
medicine, experimental (1) 1
medicine, general & internal (1) 1
metastasis (1) 1
metastatic colorectal-cancer (1) 1
metastatic pancreatic cancer (1) 1
mutation (1) 1
neoplasm metastasis - drug therapy (1) 1
oxaliplatin (1) 1
paclitaxel plus gemcitabine (1) 1
patient selection (1) 1
patients (1) 1
phenotype (1) 1
phosphatidylinositol 3-kinases - blood (1) 1
phosphatidylinositol 3-kinases - genetics (1) 1
placebo plus (1) 1
plasma (1) 1
plus (1) 1
plus irinotecan (1) 1
precision medicine (1) 1
predictive value of tests (1) 1
prognosis (1) 1
proportional hazards models (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 937 - 948
Summary Background Tumour mutational status is an important determinant of the response of metastatic colorectal cancer to targeted treatments. However, the... 
Hematology, Oncology and Palliative Medicine | KRAS MUTATIONS | 1ST-LINE TREATMENT | LEUCOVORIN | PLUS IRINOTECAN | ONCOLOGY | RANDOMIZED PHASE-III | INHIBITS GROWTH | ACQUIRED-RESISTANCE | FLUOROURACIL | PLACEBO PLUS | TUMOR-GROWTH | Predictive Value of Tests | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Clinical Trials, Phase III as Topic | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Real-Time Polymerase Chain Reaction | Precision Medicine | Receptor, TIE-1 - blood | Phosphatidylinositol 3-Kinases - blood | Genetic Predisposition to Disease | Adenocarcinoma - blood | ras Proteins - blood | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Disease Progression | Phenotype | Class I Phosphatidylinositol 3-Kinases | Biomarkers, Tumor - genetics | ras Proteins - genetics | Patient Selection | DNA, Neoplasm - blood | Female | Adenocarcinoma - genetics | Retrospective Studies | Pyridines - therapeutic use | Colorectal Neoplasms - mortality | Colorectal Neoplasms - blood | Kaplan-Meier Estimate | Proportional Hazards Models | Phenylurea Compounds - therapeutic use | Proto-Oncogene Proteins B-raf - blood | Proto-Oncogene Proteins - genetics | Treatment Outcome | Randomized Controlled Trials as Topic | Biomarkers, Tumor - blood | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Proto-Oncogene Proteins B-raf - genetics | Aged | DNA, Neoplasm - genetics | Colorectal Neoplasms - pathology | Proto-Oncogene Proteins - blood | Adenocarcinoma - mortality | Medical colleges | Medical research | Cancer patients | Prognosis | Liver | DNA | Colorectal cancer | Genetic research | Medicine, Experimental | Metastasis
Journal Article
Journal Article
Oncology, ISSN 0030-2414, 12/2017, Volume 93, Issue 6, pp. 367 - 376
Objectives: Carbohydrate antigen 19-9 (CA19-9) is a sensitive and specific serum marker in pancreatic cancer. Our retrospective analysis aims to evaluate... 
Clinical Study | Biomarkers | FOLFIRINOX | CA19-9 | Metastatic pancreatic cancer | SURVIVAL | ADENOCARCINOMA | CANCER | CHEMOTHERAPY | ONCOLOGY | PACLITAXEL PLUS GEMCITABINE | CARBOHYDRATE ANTIGEN 19-9 | CA-19-9 | TUMOR-MARKER
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.